<DOC>
	<DOCNO>NCT00329329</DOCNO>
	<brief_summary>The purpose study determine maximally tolerate dose ( MTD ) Phase 2 recommend dose satraplatin administer combination capecitabine patient advance solid malignancy .</brief_summary>
	<brief_title>Study Satraplatin With Capecitabine Treat Advanced Solid Malignancies</brief_title>
	<detailed_description>This single center , open-label , non-randomized , Phase I dose find study investigational , oral cytotoxic drug , satraplatin combination capecitabine patient advance solid tumor curative therapy available . Please refer Eligibility Criteria key inclusion exclusion criterion . PURPOSE : The purpose trial determine tolerable dose schedule combination satraplatin docetaxel give patient advance solid tumor . WHAT IS SATRAPLATIN : Satraplatin oral , investigational anticancer drug member platinum-based class chemotherapy drug . Platinum-based drug clinically prove one effective class anticancer therapy . Unlike currently market platinum-based drug , satraplatin give orally .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>Key Histologically confirm solid tumor metastatic unresectable standard curative palliative chemotherapy measure exist longer effective Age &gt; 18 year old ECOG Performance Status &lt; 2 Female patient may pregnant lactate must willing practice contraception Adequate organ function define follow : Serum creatinine &lt; 1.5 mg/dl Absolute neutrophil count ( ANC ) &gt; 1500/dL Platelets &gt; 100,000/dL Total bilirubin &lt; upper limit normal ( ULN ) reference lab AST , ALT , alkaline phosphatase must within designate range allow eligibility Key Other chemotherapy treatment &lt; 4 week prior enrollment Treatment capecitabine , 5fluorouracil ( 5FU ) , platinum agent &lt; 3 month time enrollment Radiotherapy involve &gt; 30 % active bone marrow Radiotherapy &lt; 4 week prior enrollment Preexisting peripheral neuropathy &gt; grade 1 Preexisting hearing loss &gt; grade 2 Metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry , clinically stable respect tumor time study entry , receive steroid therapy taper Patients recover ( &gt; grade 1 ) follow toxicity previous regimen enrollment : hematologic toxicity fatigue mucositis nausea/vomiting diarrhea Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Uncontrolled intercurrent illness include , limited , ongoing active infection , uncontrolled congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement History hypersensitivity reaction capecitabine , 5FU platinum contain drug History human immunodeficiency ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness Evidence concurrent second malignancy basal cell carcinoma skin cervical carcinoma situ Concurrent use medication inhibit cytochrome P450 3A4 ( include aprepitant ) History bone marrow major organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Advanced solid malignancy</keyword>
</DOC>